Evidence · idea-002

FDA (US Food and Drug Administration) CPG Sec. 655.100 ("Devices Used in Animals") states that devices intended solely for animal use are not subject to premarket notification or premarket approval

FDA retains post-market authority over animal devices under the misbranding/adulteration provisions of the FD&C Act, so labeling and claims remain an enforcement surface even without premarket review

FTO risk concentrates not in the expired foundational NPWT patents but in live patents covering canister-free / superabsorbent single-use NPWT (Smith & Nephew PICO family) and in dressing-interface chemistry

Peer-reviewed comparative result exists, and at abstract depth it is narrower and more equivocal than its title: AJVR 2022;83(10) (PMID 35973001) is an n=5 Beagle pilot on surgically created 2cm x 2cm full-thickness hemithorax wounds treated for 14 days. Control wounds developed granulation tissue faster and more abundantly, and showed greater wound contraction, epithelialization and fibroblast proliferation at study end; the authors conclude the device "is feasible but problematic in maintaining a vacuum, requiring frequent revisions of the dressing" and that "its benefits in wound healing remain unknown"

Reimbursement — there is no third-party payer code, HCPCS (Healthcare Common Procedure Coding System) or otherwise, for veterinary NPWT; revenue is cash-pay at point of service, optionally offset by pet insurance reimbursement to the owner

Pet insurance penetration in the US is under 5% of owned dogs, so insurance is not a material demand driver for a several-hundred-dollar adjunct therapy

TAM (total addressable market) component 1 — annual US caseload of canine degloving, shearing, and distal-limb wounds severe enough to warrant NPWT or free skin grafting is in the range of 30,000-80,000

TAM component 2 — realistic net selling price per single-use unit (pump plus two dressing kits) is $180-$320 to the practice

TAM component 3 — addressable share assumption: initial obtainable segment is cases managed at ACVS (American College of Veterinary Surgeons)-affiliated specialty and referral hospitals and equine surgical practices, assumed by the Generator to be roughly 20-30% of qualifying cases

Moat lever — the defensible assets are the fur-compatible adhesive drape chemistry and the chew/bandage-resistant limb interface, both patentable and both species-specific; the pump itself is a commodity and confers nothing

Fast-follower risk is structurally elevated precisely because there is no premarket review: a competitor faces no regulatory delay, only tooling and distribution

Capital intensity — first revenue is achievable for low-single-digit millions, dominated by dressing tooling, sterile packaging validation, and one or two prospective clinical case series at veterinary teaching hospitals, with no IND/IDE-equivalent required

Assumption (not a checkable fact) — the idea depends on veterinary surgeons choosing a purpose-built veterinary unit over continuing to buy human PICO units off-label at similar or lower cost. There is no connector for practitioner purchasing preference and no primary research behind this; stated here so it stays visible

Second comparative veterinary result exists, at this candidate's exact anatomical site: Equine Vet J 2022 (PMID 34115409), "Limited added value of negative pressure wound therapy compared with calcium alginate dressings for second intention healing in a noncontaminated and contaminated equine distal limb wound model" — a controlled experiment on circular wounds created on the dorsomedial metacarpus of 10 horses (5 contaminated with S. aureus and P. aeruginosa), one limb NPWT and the contralateral limb calcium alginate. In noncontaminated wounds NPWT gave significantly less wound retraction in early healing (mean difference 19.2% [95% CI 13.3-25.1], P = .005) and a significantly lower neutrophil / higher macrophage influx, with no difference in bacterial load or growth factors; in contaminated wounds no differences were observed on any measure. The authors state "[MAIN LIMITATIONS] Sample size is small" and conclude no long-term advantage over calcium alginate

Owners of dogs with severe distal-limb wounds will pay several hundred dollars out of pocket for an adjunct wound therapy on top of the surgical bill

A dog will tolerate a pump-and-drape assembly on a distal limb for the full treatment period under normal home conditions, without removing or chewing it off

Veterinary technicians can apply a fur-compatible drape and achieve a working seal reliably in ordinary practice conditions, without specialist training or adhesive spray

Specialty and referral practices are willing to dispense an adjunct wound device for post-discharge management by the owner at home, rather than keeping the animal hospitalised

Veterinary practices currently buy human single-use NPWT units off-label at a unit price comparable to the proposed veterinary-specific unit

A veterinary-specific NPWT unit can be carried by the major US veterinary distributors and reach specialty and equine practices through them

Gross margin at the proposed practice price supports a distributor sales motion after dressing cost of goods and sterile packaging validation

A fur-compatible adhesive drape can hold a seal at approximately -80 mmHg (millimetres of mercury) on a canine or equine distal limb for at least 72 hours of normal ambulation

The limb-conforming interface layer survives normal animal behaviour and standard bandage-over-dressing practice without loss of seal

Adhesive and drape contact on furred distal-limb skin produces irritation below the level that hampers attainment of negative pressure

Sterile packaging and single-use dressing tooling can be validated to a standard that supports the labelled claims, in the absence of any premarket review

In a retrospective clinical-setting study of human NPWT patients, 20% ceased NPWT prematurely at their own request, citing experienced limitations in daily activities

In a systematic review of 29 studies (n=5,614 human surgical patients), single-use canister-free NPWT (PICO) reduced surgical-site infection (OR 0.37), wound dehiscence (OR 0.70), seroma (OR 0.23) and necrosis (OR 0.11) versus conventional dressings

In a retrospective matched-pairs comparison of 50 dogs, wounds treated with NPWT had significantly fewer complications (p=0.008) and significantly less sepsis (p=0.016) than wounds treated with a foam dressing, and healed faster than conventional bandaging

In a retrospective case series of 7 dogs receiving portable single-use canister-free NPWT after distal-extremity free skin grafts, the only complication recorded was fluid accumulation in the evacuation tubing, and all 7 dogs achieved 100% graft survival

In a retrospective case series of 42 horses treated with NPWT for limb wounds (mean application 11.5 days), 69% (29/42) had satisfactory healing at discharge, 26% (11/42) were discharged before NPWT was considered ideally complete, and 2/42 were euthanized post-surgery for unrelenting pain

51% (19 of 37) of FDA device recalls for canistered NPWT powered suction pumps (product code OMP) initiated 2011-08-31 through 2026-08-27 name a canister, dressing-connector, or tubing defect as the stated recall reason

In a retrospective case series of 8 dogs receiving full-thickness mesh skin grafts bolstered with NPWT and PVA foam, 1 of 8 dogs had a bandage complication after NPWT cessation that caused partial graft loss, while 7 of 8 achieved excellent graft take

A 2026 equine wound-healing commentary states that isolated use of PICO-system NPWT in a small case series was not sufficient to stimulate healing, with no reduction in wound size observed, and that recent literature reviews found no solid evidence on best practices for equine distal-limb wound healing, calling many results controversial

The equine segment (caseload, price, and obtainable share) materially enlarges the addressable US revenue pool beyond the canine-only estimate in the file's TAM components, and the canine and equine figures are commensurable enough to sum.

First commercial revenue (first unit sold or first paid rental episode) is reachable within a calendar window commensurate with the file's low-single-digit-millions capital estimate for reaching first revenue.

An existing NPWT-platform maker or veterinary NPWT rental vendor would pay a royalty or transfer price for a validated fur-compatible drape and limb-interface module rather than declining to integrate a third-party component.

A per-treatment rental or service fee a practice or owner would pay covers a technician's application, retrieval and reprocessing labor cost and still yields positive margin to whoever runs the service.

A commercial launch narrowed to canine free-skin-graft cases only requires a materially smaller or shorter prospective case series than the one or two case series the full-indication capital estimate assumes.

Distribution relationships with major US veterinary distributors sufficient to reach ACVS-affiliated specialty/referral and equine surgical practices can be built within the capital and calendar the file's capital-intensity estimate describes.

A bench-plus-in-vivo seal-duration study of at least 15 dogs and 15 horses, applying the candidate's fur-compatible adhesive drape and limb-conforming interface to open or grafted distal-limb wounds and measuring maintenance of therapeutic sub-atmospheric pressure with no more than one unscheduled dressing failure per 72-hour wear interval over a minimum 5-day treatment course, demonstrates the interface avoids the adhesion/seal failure mode already documented for the closest existing canister-free analog (PICO) in these species.

A prospective controlled study comparing the candidate's canister-free NPWT device against current standard of care (conventional bandaging in dogs, or calcium alginate dressing in horses) in at least 20 dogs and/or 20 horses with open or free-skin-grafted distal-limb wounds, using wound closure time or graft survival rate as the primary endpoint over a minimum 4-week follow-up, shows a favorable effect versus standard of care at this candidate's targeted site and indication.

FDA retains post-market authority under FD&C Act Secs. 501 (adulteration) and 502 (misbranding) over this device's labeling and therapeutic-effect claims notwithstanding the absence of premarket review, and that authority is exercised in practice against animal-only devices per FDA's stated enforcement posture

The fur-compatible adhesive drape and the chew/bandage-resistant limb-conforming interface can be combined into a single wear assembly on a canine or equine distal limb without either component's own fix (greater fur-sealing tack vs. greater mechanical/chew toughness) degrading the other's performance, i.e. the two unbuilt components pass a combined-assembly bench and in-vivo test, not only independent component tests.

The capital-intensity estimate for reaching first revenue excludes battery/electrical-safety qualification for the disposable powered pump subassembly and biocompatibility/skin-irritation qualification for the fur-compatible adhesive drape, both of which are additional cost and schedule items beyond dressing tooling and sterile-packaging validation.

No HCPCS Level II code, CPT (Current Procedural Terminology) code, or Medicare/Medicaid coverage determination can apply to a device used exclusively in veterinary medicine, because CMS code assignment and Medicare (Title XVIII)/Medicaid (Title XIX) coverage under the Social Security Act are scoped to services furnished to human beneficiaries -- this is a structural exclusion of the entire device category, not an unfilled code request for this specific device

The low-single-digit-millions capital estimate to reach first revenue funds tooling and process qualification at a production scale and unit cost of goods that supports the 180-320 dollar practice price after dressing COGS and a distributor margin stack, not merely a pilot-volume build sufficient for one or two case series.

US pet insurers adjudicate indemnity claims against the itemized veterinary invoice rather than by matching a HCPCS/CPT procedure code, so the absence of a CMS code does not by itself preclude an owner from being reimbursed by pet insurance for this device

At least one major US pet insurer's policy language does not categorically exclude negative-pressure wound therapy or wound-care adjunct devices as experimental, investigational, or elective, in a way that would make this candidate's intended-use wounds (open, contaminated, or free-skin-grafted distal-limb wounds) non-reimbursable

A single adhesive/coating formulation and a single qualified converter or coating house are what the fur-compatible drape depends on for supply, with no second source named anywhere in the file.

The capital estimate for reaching first revenue (claim 18unconfirmed) excludes ground-up bench and in-vivo development spend for the fur-compatible adhesive drape chemistry and the chew/bandage-resistant limb interface -- the material-science formulation and design-iteration work needed to arrive at a working component in the first place -- because claim 18unconfirmed names only dressing tooling, sterile packaging validation, and clinical case series as cost drivers, and production tooling presupposes a frozen design that does not yet exist for either component.

The joint between the pump/tubing and the dressing/limb-conforming interface in this candidate's design (the connector or port) does not exhibit the port/connector failure mode already recorded in the closest canister-free analog's own recall history (the six 2014 Smith & Nephew 'Soft Port' recalls identified in claim 37unconfirmed's dataset, describing a sealing/port failure adjacent to a dressing connector) or the broader canister/connector/tubing defect share (19/37, 51%) recorded across the human-use product-code-OMP recall history.

A design-input specification for the disposable battery-powered pump subassembly -- battery chemistry and capacity, a named target electrical-safety standard, motor/pump duty cycle, and negative-pressure control tolerance -- exists as a document distinct from the dressing/drape system's own design inputs, rather than the pump being carried in the design record only as an unspecified commodity component.

The dressing-tooling and packaging-validation capital named in claim 18unconfirmed (low-single-digit millions, scoped to one or two prospective clinical case series) funds production capacity at a scale sufficient to manufacture units at the cost of goods that supports the $180-$320 net selling price in claim 14unconfirmed with positive gross margin after a distributor's own cut, rather than funding pilot-volume tooling only that would require a second, larger capital raise before commercial-scale cost of goods is reachable.

The NPWT system used in PMID 34115409 (Equine Veterinary Journal 2022) is a canister-free single-use device rather than a conventional canistered pump system, and this study's unfavorable finding at this candidate's exact anatomical site therefore generalizes to the canister-free form factor specifically.

21 U.S.C. §§ 351 (adulteration) and 352 (misbranding) — the codification of FD&C Act §§ 501/502 — apply their grounds to 'a drug or device' with no human-use qualifier in their introductory text, in textual contrast to 21 CFR 807.20(a)/807.81(a)/814.1(a)'s express limitation to devices intended for human use

A claim-chart comparison of the candidate's canister-free NPWT dressing design against the independent claims of US9061095B2, US11395870B2, and US12453658B2 (Smith & Nephew family), including any continuation, divisional, or foreign family members, finds no literal or doctrine-of-equivalents infringement, or identifies an available design-around.

The mean pump ON-time duty cycle for a canister-free NPWT pump maintaining -80 mmHg through a superabsorbent dressing on an ambulatory canine or equine distal limb does not exceed 7% of elapsed time over any 24-hour period -- which is the duty figure the pump subassembly design-input specification's 6 Wh usable primary-cell energy budget and its 7-day single-use therapy duration are sized against, and above which the pack is exhausted before the therapy period ends.

A diaphragm pump and closed-loop pressure control of the size, cost and energy class a single-use disposable subassembly permits holds the therapy setpoint at -80 mmHg within a +/-10 mmHg control band measured at the dressing port (not at the pump outlet), with an independent hardware limit that prevents pressure more negative than -110 mmHg under any single fault including firmware failure, on an ambulatory canine or equine distal limb.

UN Manual of Tests and Criteria Part III sub-section 38.3 qualification -- required by 49 CFR 173.185 before a lithium cell or battery may be offered for transport -- and FCC equipment authorisation under 47 CFR Part 15 Subpart B as an unintentional radiator, with no exemption available under 47 CFR 15.103, are third-party test regimes that attach to this pump subassembly for US shipment and sale notwithstanding that the finished device is labeled solely for veterinary use; an alkaline-cell variant of the same pump falls outside 49 CFR 173.185 entirely.

IEC 62133-2 ('Secondary cells and batteries containing alkaline or other non-acid electrolytes -- Safety requirements for portable sealed secondary lithium cells, and for batteries made from them, for use in portable applications -- Part 2: Lithium systems') is scoped to portable sealed SECONDARY, i.e. rechargeable, lithium cells, and therefore does not apply to the primary non-rechargeable cells a single-use disposable pump carries; the applicable cell-safety standard for primary lithium cells is IEC 60086-4, 'Primary batteries -- Part 4: Safety of lithium batteries'.

IEC 60601-1 is within scope for a veterinary-only device by the standard's own terms -- its definition of PATIENT is a 'living being (person or animal)' receiving healthcare services, with an explicit note that safety limit values can differ for non-human patients -- so naming IEC 60601-1 and its collateral IEC 60601-1-11 (home healthcare environment) as design targets for this pump subassembly is a voluntary contractual and product-liability choice, not a scope exclusion and not a regulatory obligation.

Market-model leg — in a cash-pay veterinary market the owner is the payer, so the share of clinically-eligible canine and equine distal-limb wound cases that converts into a paid adjunct NPWT course once the owner is quoted the price is a distinct multiplicative step strictly below 100 percent, and it is a step this candidate's own TAM decomposition (claims 13, 14 and 15) omits entirely rather than bounds

The published structured abstract of Haspeslagh et al., Equine Veterinary Journal 2022;54(3):592-600, names no NPWT device, manufacturer, model, pressure setting or form factor anywhere in its text, including its Methods paragraph

Table 2 of Cantatore et al. 2023 ("List of the NPWT devices which were used in the studies considered in the review and their manufacturers") attributes the NPWT system "VAC ATS", manufacturer printed as "KCL Medical", to the Haspeslagh et al. equine distal-limb wound study, on a row that also misspells the author name as "Haspelaslagh" and gives the year as 2020 against a 2022 journal issue

Kamus et al. 2019 reported that "All horses readily tolerated the PICO(R) but difficulties with adhesion and seal prevented the completion of the experimental wound study despite the use of many adjunctive adhesives" — the one published equine trial of a canister-free single-use NPWT device, which did not reach its endpoint

A 2025 review of NPWT in equine wound treatment tabulates the Haspeslagh et al. equine distal-limb study and records no device or manufacturer for it, its device field reading "Data not presented"

FDA classified recall Z-1474-2024 as Class II on 2024-04-03, covering 147 units of a Karl Storz Endoscopy product whose FDA recall record describes it as "Karl Storz SE & CO. KG, REF 723014, Uvula Retractor, For Veterinary Use Only, Rx Only", for inadequate reprocessing validation evidence

FDA classified recall Z-1911-2020 (ICU Medical, REF AH7117 IV administration set, FDA recall record product description "For Veterinary Use Only") as Class II, recorded as firm-initiated, report date 2020-05-13

FDA classified recall Z-1640-2022 (bioMerieux VITEK 2 software versions 8.01 and 8.02, FDA recall record product description "veterinary use only") as Class II, recorded as firm-initiated, report date 2022-09-07

Federal Register notice E6-10672 (71 FR 38650, published 2006-07-07) withdrew CPG 7125.35, entitled "Human-Labeled Drugs Distributed and Used in Animal Medicine", as obsolete — a drug-distribution guide, not a device guide, and not CPG Sec. 655.100

All three FDA device-enforcement records whose product description contains "veterinary use only" are recorded as "Voluntary: Firm initiated" rather than FDA-mandated, and a query combining voluntary_mandated:"FDA Mandated" with a veterinary product description returned no matching record — an absence of an FDA-mandated action, which is silence and not evidence of a hands-off enforcement posture

US Patent 9,061,095 B2 Veterinary surgeons switch from the human… ("Wound dressing and method of use", Smith and Nephew PLC, filed 2011-04-21, granted 2015-06-23) is listed active with an expiration date of 2033-10-27, and its claim 1unconfirmed recites a wound treatment apparatus with a wound-contact layer, a transmission layer, an absorbent layer, a gas-impermeable moisture-vapor-permeable cover layer, and a suction port with a filter element

US Patent 11,395,870 B2 Veterinary surgeons switch from the human… (T.J Smith and Nephew Ltd, filed 2018-02-15, granted 2022-07-26) is listed active with an expiration date of 2039-01-22, and its claim 1unconfirmed recites a controller that detects via a switch at the connector port whether a canister or a canisterless wound dressing is attached and adjusts operation accordingly

US Patent 12,453,658 B2 Veterinary surgeons switch from the human… ("Absorbent Negative Pressure Wound Therapy Dressing", Smith and Nephew PLC, granted 2025-10-28) is listed active with an expiration date of 2040-01-11, and its claim 1unconfirmed recites a backing layer with an opening, adhesive or glue on the backing layer's upper surface, and an absorbent layer between the backing layer and the wound site, with no species or human-use limitation in the claim or the retrieved summary

US Patent 12,447,258 B2 Veterinary surgeons switch from the human… (Moelnlycke Health Care AB, granted 2025-10-21) is listed active with an expiration date of 2042-09-26, and claims a backing layer, an adhesive skin-contact layer and an absorbent structure with superabsorbent polymer particles at 10-20 mg/cm2, designed to connect to a remote fluid collection means rather than being canister-free

US Patent 7,004,922 B1 The wear system holds a working seal at…, an animal wound wrap that names fur explicitly and states its purpose as eliminating adhesive entirely by means of a hook-and-loop stretchable wrap, is listed expired (fee-related) as of 2024-04-09

US Patent 11,260,164 B2 Veterinary surgeons switch from the human… (Genesis Medical Devices LLC, granted 2022-03-01) is listed active with an expiration date of 2038-12-04 and claims a compressible, diameter-adjustable NPWT connector/adaptor for human use, not fur- or limb-shape-specific

A KCI USA, Inc. "Snap Therapy System Snap 125mmHg Therapy Cartridge 60ml" — a single-use, portable, non-electric-canister NPWT format — is registered in FDA's Global Unique Device Identification Database under primary DI 00849554006058

California Insurance Code section 12880.2 requires a pet insurer to disclose, before sale, the "basis or formula on which the insurer determines claim payments", any applicable benefit schedule, and any usual-and-customary basis — three bases, naming no procedure-coding system. Note this is California state law, not a US federal registry record, so no federal typed connector reaches it

California Insurance Code section 12880's pet-insurance definitional list runs thirteen defined terms, (a) through (m), and contains no definition of a benefit schedule, a usual-and-customary basis, or any procedure-coding system. Note this is California state law, not a US federal registry record

FDA recall Z-0009-2013 (Accuro Medical Wound Pro Apex) states the pump could fail or malfunction without notifying the user via the unit's display screen — a pump-subassembly failure mode, not a canister failure mode

FDA 510(k) K161128 (Medela AG, Invia Motion NPWT system family) was cleared 2016-12-01

FDA recall Z-2528-2018 (Medela Invia Motion) was initiated because the device may display a battery missing error — a pump/battery failure mode that a single-use canister-free design does not remove

FDA recall Z-2543-2020/Z-2544-2020 (Cardinal Health 200, LLC NPWT canisters) states the canisters potentially contain an oversized O-ring that cannot be installed into the device's mating connector

Injury, wounds, and trauma accounted for 27.8% of deaths in US resident equids under 1 year of age and 16.3% of deaths in equids 1 to less than 20 years of age, in a nationally representative 2015 USDA survey covering 28 states and 71.8% of all US equids

ASPCA Pet Health Insurance's published coverage page states that "Complete Coverage(SM) reimbursements are based on the invoice", while preventive care reimbursements are "based on a schedule", and names no procedure code anywhere

ASPCA Pet Health Insurance's veterinary-facing FAQ describes claim submission as records-and-invoice rather than coded: "Typically the pet owner pays the veterinarian at the time of service, and then the pet owner submits a claim for reimbursement", with the instruction "Please include 12 months of medical records with your submission"

Healthy Paws' published coverage-and-exclusions page states "Reimbursements are based on your actual veterinary bills"

Healthy Paws' published exclusions list names pre-existing conditions, preventive healthcare, elective procedures, boarding, behavioral modification, training and examination fees, and names neither negative-pressure wound therapy, wound-care devices, prosthetics, nor experimental or investigational treatment — an absence of retrieved wording, not a grant of coverage

ASPCA Pet Health Insurance's published elective-procedure exclusion is exemplified only by tail docking, ear cropping and claw removal, and its published coverage page names no exclusion for experimental or investigational treatment or for devices — an absence of retrieved wording, not a grant of coverage

Nationwide's public pet-insurance product page states only "Some exclusions may apply. Certain coverages may be excluded due to pre-existing conditions. See policy documents for a complete list of exclusions", naming no exclusion category relevant to wound care and stating no adjudication basis beyond reimbursement of eligible expenses after the annual deductible

The American College of Veterinary Surgeons reports 2,686 board-certified Diplomates following its February 2026 certification exam, with 44.54% reporting small-animal general/orthopedic emphasis and 42.37% equine general/orthopedic emphasis (Diplomates may select more than one emphasis, so these do not convert to a headcount split)

The American Association of Equine Practitioners reports more than 9,000 veterinarians and veterinary students as members on its own about page

A 2023 list-price cost-and-metric comparison of disposable NPWT systems found the no-canister PICO 14 the most cost-effective system evaluated at $25.00 per day of therapy, against more than $180 per day for two named 3M/KCI systems (V.A.C. Via and Prevena Plus) — a per-day figure the abstract does not translate into a per-unit price

Human-labeled Smith & Nephew PICO 7 single-use NPWT dressing kits (10x30 cm, one dressing) were listed at retail cash-pay prices of $378.69 and $388.13 across two independent, non-affiliated US medical-supply retailers on 2026-09-13, an approximately $367-$431 per-unit range across sizes — retail human-market pricing, not a veterinary net price to a practice

NAPHIA's 2026 State of the Industry Report Highlights states a US dog pet-insurance penetration rate of 5.99% for year-end 2025, against 2.29% for cats and 4.27% for all US pets, on a denominator NAPHIA states as approximately 87.3 million dogs and 76.3 million cats owned in the US

NAPHIA's prior-year State of the Industry release states US penetration rates of 5.46% for dogs and 2.04% for cats at year-end 2024, so both of NAPHIA's two most recent dated dog-specific figures are above 5%

The NHS (National Health Service) Supply Chain unit cost of the PICO NPWT system was reported as GBP 147.06, averaged across the various dressing sizes available — a UK bulk-procurement price for a completed device, not a bill of materials and not a US price

Mean US Medicare payment per disposable NPWT treatment episode was $1,532 (SD $1,767; n=3,522 episodes, mean age 67.6 years, 2012-2014 national claims) against $4,650 (SD $2,782; n=2,938) per traditional durable-canister NPWT episode, P<.0001

A decision-tree cost-minimization model of two durable canister-based NPWT technologies reported total expected per-patient costs of $41,206 (SD $8,194) for Cardinal Health PRO and $44,439 (SD $8,963) for V.A.C. ULTA — a full hospital episode, not a device unit cost or a distributor margin

Covetrus's public wound-care catalog category "Woundcare Other" listed no negative-pressure wound therapy device of any kind as of 2026-09-13, showing only a bitter-taste deterrent spray (SKU 2801490) and two sizes of Manuka honey wound gel (SKUs 2800417, 2800418)

Patterson Veterinary's public catalog search returned "No Search Results Found" for both "wound vac" and "PICO" as of 2026-09-13

Midwest Veterinary Supply's public catalog search returned no product results for either "wound vac" or "PICO" as of 2026-09-13, surfacing only seven unrelated instructional videos

A direct-to-veterinary-practice vendor, The Wound Vac Company, offers a "WoundPro" NPWT system (Control Unit, WoundPro+ and a portable MicroDoc unit) for rental or purchase with stock held in Florida and Atlanta warehouses, alongside a separate WoundPro canister consumable line — a channel that reaches US practices outside the three named national veterinary distributors

In a prospective randomized trial of 26 dogs, NPWT-treated wounds closed significantly faster (mean 14.2 days) than silver-coated foam dressing-treated wounds (mean 28.6 days), p=0.018 — the comparator is a silver foam dressing, not conventional bandaging and not a canister-free device

A 2024 scoping review of 81 manuscripts on equine second-intention wound healing found that only 36% of experimental studies (n=59) showed statistically significant healing improvement versus control

In a retrospective case series of 7 dogs treated with a portable single-use NPWT device after full-thickness meshed skin grafts to the distal extremity, NPWT was applied for 4-7 days and 5 of the 7 dogs were discharged from hospital during the treatment period

In a retrospective case series of 42 horses treated with NPWT for limb wounds, wounds were classified as 36% bony (15/42), 33% articular (14/42), 21% tenosynovial (9/42), 5% muscular (2/42) and 5% cutaneous (2/42), with second-intention healing the indication in 74% (31/42) of cases

In a UK NHS case series of 5 human patients with open lower-limb wounds, a single-use NPWT discharge pathway produced an average inpatient length-of-stay reduction of 20.2 days and a projected GBP 12,350 hospital-cost saving per patient versus patients who remained hospitalised until community NPWT was available — a human, non-US, n=5 analog for the send-home pathway, not evidence about dogs or horses

The top three causes of canine trauma across 22 North American and UK Veterinary Trauma Centers in 2022-2023 (n=8,130 dogs) were penetrating bite wounds (35%), vehicular strikes (17%) and lacerations (12%)

The prevalence of road traffic accidents among dogs attending 115 UK primary-care veterinary practices (n=199,464 dogs, 2009-2014) was 0.41%, with 22.9% of RTA cases dying from an RTA-associated cause — a UK primary-care denominator, not a US one

In an owner-reported cohort of 219 horses with traumatic wounds, the most common wound cause was wire/fence injury (38%, 84/219) and the most common wound location was the distal hindlimb (31%, 79/251 wounds)

A 2021 US survey of 306 uninsured dog owners found 44% willing to spend up to $1,000 and 46% willing to spend $3,000 or more to prolong their pet's life by a year — stated willingness to spend, not a recorded purchase, and not scoped to wound care

A retrospective study of 260 dogs with gastric dilatation-volvulus across 24 US emergency clinics found a pre-surgical euthanasia rate of 10% in insured dogs versus 37% in uninsured dogs (p<0.001)

A 2017 JAVMA survey of 1,122 US and Canadian small-animal veterinarians found 57% (620/1,088) reported client economic limitations affected their ability to provide desired patient care on a daily basis

A 2020 US logit-model study found that pet health insurance had a significant and positive impact on the amount dog owners spent at the veterinarian

A US pet insurer would in practice reimburse an owner for a veterinary negative-pressure wound therapy course applied to an open, contaminated or free-skin-grafted distal-limb wound. Recorded, not researched and not answered: it asks what an adjudicator would do. Its revealed-behaviour twin was researched instead and is carried at claims 101-106 — what each insurer's published wording states as its adjudication basis and what its exclusion list does and does not name. Two insurers are SILENT on wound-care and device categories and one was not retrieved at all; silence in a published exclusion list is not permission

FDA would exercise its FD&C Act adulteration/misbranding authority against an animal-only NPWT device's labelling or therapeutic-effect claims. Recorded, not answered: it asks what an agency would do. It was deliberately split into two answerable questions instead — what a retrievable document states (CPG Sec. 655.100's text was not retrieved from any reachable host, so nothing is asserted about its wording) and what a retrievable record shows FDA did (three Class II classifications of veterinary-labelled devices, all firm-initiated, at claims 79-83). No FDA-mandated action against an animal-only device was found, which is silence and not a hands-off posture

Owners will keep a pump-and-drape assembly in place on a dog's or horse's distal limb through an unsupervised home phase of several days without removing it themselves before the treatment course ends

Owners will recognise and act on a loss-of-seal or device-failure indication on a single-use NPWT pump during the home phase without a veterinary technician present

A post-discharge veterinary NPWT course requires no additional in-clinic recheck visit between application and removal, so it adds no clinic-visit cost to the owner beyond the price of the device

US veterinary specialty and referral practices will hold single-use NPWT units as shelf stock and bear the inventory risk of units that expire unused

A claim-chart comparison of the candidate's drape, limb-conforming interface and pump-to-dressing connector against the independent claims of US12447258B2 (Moelnlycke Health Care AB) and US11260164B2 (Genesis Medical Devices LLC) finds no independent claim that reads on the candidate's design

A veterinary-specific single-use canister-free NPWT unit can be manufactured and sold into practices at the 180-320 dollar practice price asserted at claim 14unconfirmed without a human-market volume base to amortise dressing tooling and sterile packaging validation against

The adhesion and seal failure that prevented completion of the Kamus et al. 2019 equine PICO trial is attributable to the drape and adhesive system rather than to the canister-free architecture itself, so a purpose-designed fur-compatible drape addresses it

A veterinary-labelled canister-free NPWT device can be labelled and used for post-discharge management outside a healthcare facility, notwithstanding that the human NPWT predicate at claim 94verified carries an indications-for-use statement limiting it to healthcare-facility use

A single-use pump subassembly containing a lithium primary cell can be disposed of by a US veterinary practice or an animal owner under applicable federal and state waste rules without a manufacturer take-back program

A US veterinary specialty or referral practice bills a single-use per-case wound-care consumable through to the animal's owner at a markup over its own acquisition cost, so the owner-facing price of a veterinary NPWT course is materially above the $180-$320 practice price asserted at claim 14unconfirmed

The share of owners presenting NPWT-eligible canine distal-limb wounds at ACVS-affiliated specialty and referral hospitals who carry pet insurance at the point of service is materially higher than the US population-wide dog pet-insurance penetration rate recorded at claims 111 and 112

An equine surgical practice bills a single-use NPWT device to the horse's owner as an itemized per-case supply line, rather than absorbing it into a per-day hospitalisation or standing-sedation charge, so the equine half of this market is a per-unit device sale on the same commercial terms as the canine half

In the candidate's plausible ex-US secondary markets, veterinary wound care is paid by the animal's owner in cash with optional private pet-insurance indemnity, and no national payment system (UK NHS/NICE, German G-DRG or NUB) reaches a veterinary-labelled device at all

A direct-to-practice sales motion that bypasses the three national US veterinary distributors can reach ACVS-affiliated specialty/referral and equine surgical practices at a customer-acquisition cost per practice below the first-year gross margin that practice generates on unit volume